Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.98)
# 50
Out of 5,182 analysts
37
Total ratings
81.82%
Success rate
90.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Initiates: Overweight | $12 | $7.03 | +70.70% | 1 | Mar 24, 2026 | |
| ERAS Erasca | Maintains: Overweight | $11 → $18 | $19.15 | -6.01% | 3 | Mar 13, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $120 → $115 | $115.07 | -0.06% | 4 | Feb 26, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $75 → $120 | $131.67 | -8.86% | 2 | Feb 26, 2026 | |
| TNGX Tango Therapeutics | Maintains: Overweight | $11 → $14 | $26.33 | -46.83% | 2 | Jan 16, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $42 → $30 | $15.23 | +96.98% | 2 | Jan 16, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $70 | $66.82 | +4.76% | 2 | Jan 16, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $9 → $8 | $2.92 | +173.97% | 2 | Jan 16, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $4.99 | +380.96% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $10.19 | +115.90% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $128 | $104.04 | +23.03% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $21 | $22.12 | -5.06% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $23.77 | +51.45% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $22.48 | +60.18% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.25 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.57 | +211.89% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.05 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $23.65 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.43 | - | 1 | Oct 31, 2022 |
Relmada Therapeutics
Mar 24, 2026
Initiates: Overweight
Price Target: $12
Current: $7.03
Upside: +70.70%
Erasca
Mar 13, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $19.15
Upside: -6.01%
Arcellx
Feb 26, 2026
Downgrades: Neutral
Price Target: $120 → $115
Current: $115.07
Upside: -0.06%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $75 → $120
Current: $131.67
Upside: -8.86%
Tango Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $11 → $14
Current: $26.33
Upside: -46.83%
Janux Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $42 → $30
Current: $15.23
Upside: +96.98%
CG Oncology
Jan 16, 2026
Maintains: Overweight
Price Target: $55 → $70
Current: $66.82
Upside: +4.76%
Black Diamond Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $9 → $8
Current: $2.92
Upside: +173.97%
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $4.99
Upside: +380.96%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $10.19
Upside: +115.90%
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $104.04
Upside: +23.03%
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $22.12
Upside: -5.06%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $23.77
Upside: +51.45%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $22.48
Upside: +60.18%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.25
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.57
Upside: +211.89%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.05
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $23.65
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.43
Upside: -